SLC6A3 and Parkinson disease: In clinical practice, PET imaging of DAT using 18F-FE-PE2I serves as a valuable, cost-effective tool early diagnosis of neurodegenerative parkinsonism, including PD, is reimbursed as routine tool in several European countries including Belgium, and is used as an imaging marker in clinical trials [13, 27].